login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
VIRIDIAN THERAPEUTICS INC (VRDN) Stock News
NASDAQ:VRDN - Nasdaq -
US92790C1045
-
Common Stock
- Currency: USD
16.8
-0.61 (-3.5%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VRDN Latest News, Press Relases and Analysis
All
Press Releases
6 hours ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 days ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
a month ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Benzinga
What 5 Analyst Ratings Have To Say About Viridian Therapeutics
2 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
3 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
7 months ago - By: Benzinga
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts
3 months ago - By: Zacks Investment Research
- Mentions:
IOVA
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
3 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
3 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
5 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
6 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
8 months ago - By: Investor's Business Daily
- Mentions:
AMGN
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
8 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
8 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
8 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
9 months ago - By: Viridian Therapeutics, Inc.
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Please enable JavaScript to continue using this application.